Digital Evidence, Real Reimbursement: DTx & RPM After the Codes

Reimbursement Turning Point

Recent CMS updates to the Physician Fee Schedule have reshaped reimbursement for remote patient monitoring (RPM) and remote therapeutic monitoring (RTM), as well as pathways for digital therapeutics (DTx). Effective January 1, 2026, new CPT codes permit billing for shorter monitoring periods and briefer clinician interactions, addressing longstanding barriers that confined many programs to limited pilots.

Previously, RPM required at least 16 days of physiologic data transmission in a 30-day period for codes like 99454, while management services needed 20 minutes of interactive time under 99457. The new framework introduces codes such as 99445 for 2-15 days of data and 99470 for the first 10 minutes of management, with payments aligned to existing rates in many cases. Parallel changes to RTM codes, including 98984 and 98985 for shorter device use periods and 98979 for abbreviated management, extend similar flexibility to therapeutic adherence and response monitoring, often tied to DTx interventions.

These adjustments follow earlier breakthroughs, including 2025 HCPCS codes (G0552-G0554) for digital mental health treatments, which enabled Medicare payment for FDA-cleared DTx addressing conditions like depression, insomnia, and substance use disorder. Proposals for 2026 further expand such coverage to ADHD devices and solicit input on broader applications, signaling regulators' intent to embed software-based care in standard payment systems.

The real-world stakes are substantial. Providers and digital health firms can now pursue reimbursement for intermittent monitoring suited to maintenance care or lower-acuity patients, potentially generating steady revenue where high compliance was once mandatory. Yet uneven adoption persists: despite policy wins, many programs struggle with infrastructure for compliant documentation, data security, and audit preparation under payer review. Successful implementations demonstrate measurable reductions in hospitalizations or improved adherence, but failures risk clawbacks or denied claims.

Tensions emerge between stakeholders. Regulators and advocates push for virtual-first models to curb costs and improve access, particularly for chronic disease management. Critics highlight variable evidence quality across DTx products and the challenge of scaling beyond pilots without consistent outcomes data. Payers, while expanding frameworks, demand proof that digital interventions deliver financial returns beyond traditional care, creating a divide between innovative promise and operational reality.